Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Cardiac injury, as measured by troponin elevation, has been reported among hospitalized coronavirus disease 2019 (COVID-19) patients and portends a poor prognosis. However, how the dynamics of troponin elevation interplay with inflammation and coagulation biomarkers over time is unknown. We assessed longitudinal follow-up of cardiac injury, inflammation and coagulation markers in relation to disease severity and outcome.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We retrospectively assessed 2068 patients with laboratory-confirmed COVID-19 between January 29 and April 1, 2020 at Tongji Hospital in Wuhan, China. We defined cardiac injury as an increase in high sensitivity cardiac troponin-I (hs-cTnI) above the 99th of the upper reference limit. We explored the dynamics of elevation in hs-cTnI and the relationship with inflammation (interleukin [IL]-6, IL-8, IL-10, IL-2 receptor, tumor necrosis factor-α, C-reactive protein) and coagulation (d-dimer, fibrinogen, international normalized ratio) markers in non-critically ill versus critically ill patients longitudinally and further correlated these markers to survivors and non-survivors.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Median age was 63 years (first to third quartile 51–70 years), 51.4% of whom were women. When compared to non-critically ill patients (<em>N</em> = 1592, 77.0%), critically ill (defined as requiring mechanical ventilation, in shock or multiorgan failure) patients (<em>N</em> = 476, 23.0%), had more frequent cardiac injury on admission (30.3% vs. 2.3%, <em>p</em> < 0.001), with increased mortality during hospitalization (38.4% vs. 0%, p < 0.001). Among critically ill patients, non-survivors (<em>N</em> = 183) had a continuous increase in hs-cTnI levels during hospitalization, while survivors (<em>N</em> = 293) showed a decrease in hs-cTnI level between day 4 and 7 after admission. Specifically, cardiac injury is an independent marker of mortality among critically ill patients at admission, day 4–7 and 8–14. Consistent positive correlations between hs-cTnI and interleukin (IL)-6 on admission (<em>r</em> = 0.59), day 4–7 (<em>r</em> = 0.66) and day 8–14 (<em>r</em> = 0.61; all <em>p</em> < 0.001) and d-dimer (at the same timepoints <em>r</em> = 0.54; 0.65; 0.61, all p < 0.001) were observed. A similar behavior was observed between hs-cTnI and most of other biomarkers of inflammation and coagulation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Cardiac injury commonly occurs in critically ill COVID-19 patients, with increased levels of hs-cTnI beyond day 3 since admission portending a poor prognosis. A consistent positive correlation of hs-cTnI with IL-6 and d-dimer at several timepoints along hospitalization could suggest nonspecific cytokine-mediated cardiotoxicity.</p>

Biomarkers associated with COVID-19 disease progression

Serum IL-6 and Procalcitonin Are Two Promising Novel Biomarkers for Evaluating the Severity of COVID-19 Patients.

Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges

Cardiovascular biomarkers in patients with COVID-19

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

Biomarkers in long COVID-19: A systematic review

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study

Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Prognosis of COVID-19: Changes in laboratory parameters

An immune-based biomarker signature is associated with mortality in COVID-19 patients

Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome

An inflammatory cytokine signature predicts COVID-19 severity and survival

Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients

Cardiac biomarkers in COVID-19: what did we learn?

Evaluation of serum and urine biomarkers for severe COVID-19

Evaluation of various blood biomarkers associated with the outcomes of patients with COVID‐19 treated in intensive care units

Proteomic blood profiling in mild, severe and critical COVID-19 patients

Cytokine Signature Associated With Disease Severity in COVID-19

Serum biomarkers for prediction of mortality in patients with COVID-19